|
|
|
Size
|
(In-person Conference) - Kingdom of Bahrain
|
Helen Kantarelis |
Tue, 30 Nov 2021 14:41:16 -0500 |
68 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Benjamin Djulbegovic MD |
Tue, 30 Nov 2021 12:25:41 +0000 |
544 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Huw Llewelyn [hul2] |
Tue, 30 Nov 2021 08:39:39 +0000 |
700 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Suhail Doi |
Tue, 30 Nov 2021 10:14:37 +0300 |
367 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Suhail Doi |
Tue, 30 Nov 2021 09:41:28 +0300 |
456 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Suhail Doi |
Tue, 30 Nov 2021 09:33:55 +0300 |
409 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Rakesh Biswas |
Tue, 30 Nov 2021 09:28:22 +0530 |
739 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Huw Llewelyn [hul2] |
Mon, 29 Nov 2021 22:52:16 +0000 |
543 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Benjamin Djulbegovic MD |
Mon, 29 Nov 2021 21:55:16 +0000 |
538 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Suhail Doi |
Tue, 30 Nov 2021 00:17:35 +0300 |
308 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Benjamin Djulbegovic MD |
Mon, 29 Nov 2021 20:02:00 +0000 |
373 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Suhail Doi |
Mon, 29 Nov 2021 22:43:07 +0300 |
190 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Suhail Doi |
Mon, 29 Nov 2021 22:35:04 +0300 |
204 lines |
Re: noncollapsibility of effect measures and interpretation in EBM
|
Benjamin Djulbegovic MD |
Mon, 29 Nov 2021 12:19:25 +0000 |
245 lines |
noncollapsibility of effect measures and interpretation in EBM
|
Suhail Doi |
Sun, 28 Nov 2021 21:43:44 +0300 |
52 lines |
Re: Consensus vs evidence-based guidelines …
|
Donald E. Stanley |
Sat, 27 Nov 2021 13:50:11 +0000 |
137 lines |
Consensus vs evidence-based guidelines …
|
Benjamin Djulbegovic MD |
Sat, 27 Nov 2021 13:19:25 +0000 |
293 lines |
Evidence & Policy: Call for Associate Editors
|
Abbie Tozer |
Thu, 25 Nov 2021 15:43:10 +0000 |
384 lines |
New MSc in EBHC Teaching and Education
|
David Nunan |
Tue, 23 Nov 2021 11:22:49 +0000 |
308 lines |
Interested in doing research on the effects of non-pharmaceutical interventions?
|
Fretheim, Atle |
Tue, 23 Nov 2021 08:28:52 +0000 |
413 lines |
Research Fellow vacancy at CHE, University of York
|
Kay Fountain |
Mon, 22 Nov 2021 14:29:48 +0000 |
40 lines |
Cariprazine and negative symptoms of Schizophrenia
|
Ali Raza Syed |
Wed, 10 Nov 2021 12:02:22 +0000 |
26 lines |
Critical Appraisal Courses
|
BLENKINSOPP, John (NORTH TEES AND HARTLEPOOL NHS FOUNDATION TRUST) |
Tue, 9 Nov 2021 08:07:56 +0000 |
72 lines |
Glasgow University: Survival/Stats HTA Courses
|
Miriam Yentumi |
Mon, 8 Nov 2021 10:38:34 +0000 |
281 lines |
THIS Institute fellowship on perioperative care is open for applications
|
THIS Institute Media |
Fri, 5 Nov 2021 17:26:47 +0000 |
189 lines |
Re: [EXTERNAL]:Medicine safety and efficacy for formulary
|
Andy Hutchinson |
Wed, 3 Nov 2021 08:51:54 +0000 |
311 lines |
Medicine safety and efficacy for formulary
|
Majid Ali |
Wed, 3 Nov 2021 07:12:16 +0000 |
192 lines |
Welcome to Academic Writing Month Resources & Writing Groups
|
Silvana di Gregorio |
Tue, 2 Nov 2021 16:39:43 +0000 |
60 lines |
Evidence officer roles at Australian National COVID-19 Clinical Evidence Taskforce
|
Tari Turner |
Mon, 1 Nov 2021 11:11:37 +1100 |
115 lines |